|Robert A. Burger, MD, FACOG, FACS|
Professor of Obstetrics and Gynecology
Director of Clinical Research
Fellowship Program Director
University of Pennsylvania
Dr. Robert A. Burger is Professor of Obstetrics and Gynecology, Director of Clinical Research, and Fellowship Program Director at the University of Pennsylvania in Philadelphia. He specializes in the care of women with gynecologic cancers. Dr. Burger is a member of the National Cancer Institute Gynecologic Cancer Steering Committee Ovarian Task Force. He is also a fellow of the American College of Surgeons and the American College of Obstetricians and Gynecologists.
Dr. Burger received his doctor of medicine degree from New York University School of Medicine in New York City. He completed a residency in obstetrics and gynecology at the University of Pennsylvania and a fellowship in gynecologic oncology at the University of California, Irvine.
Robert A. Burger, MD, FACOG, FACS, reported a financial interest/relationship or affiliation in the form of: consulting fee, Amgen, Inc., Boehringer Ingelheim, and Genentech, Inc.
|Krishnansu S. Tewari, MD, FACOG, FACS|
Professor and Director of Research
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
University of California Irvine Medical Center
Dr. Krishnansu S. Tewari is Professor and Director of Research in the Division of Gynecologic Oncology at the University of California Irvine Medical Center in Orange. He received his Bachelor of Science degree in Molecular Biology at the University of California, Berkeley. Dr. Tewari then completed medical school, a fellowship in gynecologic oncology, and a residency in obstetrics and gynecology at the University of California, Irvine. He currently serves as principal investigator of the National Cancer Institute’s NRG-Oncology Cooperative Group and Gynecologic Oncology Group Partners at the University of California, Irvine. Dr. Tewari is also a voting member of the NRG’s Cervix Committee, Publications Committee, and Committee on Experimental Medicine. He is also the Chairman of the Protocol Review and Monitoring Committee and the Director of the Gynecologic Cancer Disease Oriented Team for the Chao Family National Cancer Institute Designated Comprehensive Cancer Center. Additionally, Dr. Tewari is the Director of the Gynecologic Oncology Program at St Joseph's Center for Cancer Prevention and Treatment in Orange, California and Chairman of the Society of Gynecologic Oncology Publications Committee.
Dr. Tewari has published over 100 peer reviewed articles and written numerous book chapters. His research interests include novel targeted therapeutics in ovarian cancer and cervical cancer. Dr. Tewari is funded by the National Institutes of Health to study surrogate markers of angiogenesis in cervical cancer and is the Study Chair/Principal Investigator for Gynecologic Oncology Group protocol 240, the practice-changing phase 3 randomized clinical trial which demonstrated that compared to chemotherapy alone, the addition of the anti-angiogenesis drug, bevacizumab, significantly improved overall survival, progression-free survival, and response rate without a significant deterioration in health-related quality of life. This pivotal trial led to approval by the U.S. Food and Drug Administration on August 14, 2014, of bevacizumab in advanced cervical cancer.
Dr. Tewari has been listed for seven consecutive years as one of the Top Doctors in Orange County and has been listed in Best Doctors of America for the past 4 years. An expert in robotic surgery, for the past 2 years Dr. Tewari has been travelling every eight months to conduct robotic surgery workshops in different cities of India for women diagnosed with early stage cervical and endometrial cancer.
Krishnansu S. Tewari, MD, FACOG, FACS, reported a financial interest/relationship or affiliation in the form of: advisory board, Caris Life Sciences, Inc., ADVAXIS, and Genentech, Inc.